PPT-Sofosbuvir, Ribavirin, GS

Author : min-jolicoeur | Published Date : 2018-01-05

0938 in GT 14 QUANTUM Phase 2b Treatment Naïve Lalezari JP et al EASL 2013 Abstract 845 Source Lalezari JP et al EASL 2013 Abstract 845 Sofosbuvir Ribavirin

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Sofosbuvir, Ribavirin, GS" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Sofosbuvir, Ribavirin, GS: Transcript

0938 in GT 14 QUANTUM Phase 2b Treatment Naïve Lalezari JP et al EASL 2013 Abstract 845 Source Lalezari JP et al EASL 2013 Abstract 845 Sofosbuvir Ribavirin amp GS0938 in . ELECTRON (Overview): 6 parts, 22 arms. Phase . 2. Treatment. Naïve and Treatment . Experienced. Source: . Gilead Sciences, . Inc. Sofosbuvir. Summary of ELECTRON Trials Design (1 of 2). Part 1 . - . + Ribavirin to Prevent Post-Transplant HCV Recurrence . Phase 2. Curry . MP, et al. Gastroenterology. 2014;September 24. [. Epub. ahead of print] . Treatment. Naïve and Treatment . Experienced. Liver Transplantation. (. Epclusa. ). Prepared by. : H. Nina Kim, MD MSc and David . Spach. , MD. Last . Updated: . July . 8, . 2016. Background and Dosing. Sofosbuvir-Velpatasvir. (. Epclusa. ). Sofosbuvir-Velpatasvir. (. . + Sofosbuvir +/- Ribavirin in Genotype 1. COSMOS Trial. Phase . 2a, . Treatment . Naïve and Treatment Experienced. Treatment. Naïve and Treatment . Experienced. Lawitz. . E. , et al. Lancet. 2014;384;1756-65.. Genotype . 2. . or 3 . FUSION. Trial. Phase . 3. *Note: Published . in . NEJM in tandem . with . POSITRON Trial (GT 2,3 Unable to receive PEG). Treatment. . Experienced. Jacobson I, et al. N . Engl. ION-4. Phase . 3. Treatment. Naïve and Treatment . Experienced. Naggie. S, . et al. . N . Engl. J Med 2015;378:705-13.. HIV Coinfection. Source: . Naggie. S, et al. N . Engl. J Med 2015;378:705-13.. HIV Coinfection & HCV . GT 1,2,3. PHOTON-1 Trial. Phase . 3. Sulkowski. MS, et al. JAMA. 2014;312:353-61.. Treatment. Naïve and Treatment . Experienced. HIV Coinfection. Source: . Sulkowski. MS, et al. JAMA. 2014;312:353-61.. SIRIUS. Phase . 2 . Treatment. . Experienced. Bourliere. M, et al. Lancet Infect Dis. . 2015;15:397-404.. Source: . Bourliere. . M, . et al. . Lancet Infect Dis. 2015;15:397-404.. Ledipasvir-Sofosbuvir in Treatment-Experienced . . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . in Genotype 3. ASTRAL-3. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-2 Trial. Source: Foster GR, . ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology . 2015;148:100-7. Treatment Naïve and Treatment Experienced Liver Transplantation Source: Curry MP, et versus. Interferon alfa-2b + Ribavirin. Phase 3. Treatment. . Naïve, Chronic HCV. Fried MW, . et al. N . Engl. J Med. . 2002;347:975-. 8. 2. .. Peginterferon +/- Ribavirin versus Interferon + . Ribavirin. SOLAR-2. Source: . Manns. M, et al. Lancet Infect Dis. 2016;16:685-97.. Treatment Naïve and Treatment Experienced, Phase 2. Ledipasvir-Sofosbuvir + Ribavirin in Advanced Liver Disease. SOLAR-2: Features.

Download Document

Here is the link to download the presentation.
"Sofosbuvir, Ribavirin, GS"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.